This article is intended for primary care clinicians, gynecologists, and other specialists who care for women who use intrauterine devices.
The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this enduring material for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should claim only credit commensurate with the extent of their participation in the activity.
This enduring material activity, Medscape Education Clinical Briefs, has been reviewed and is acceptable for up to 300 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins September 1, 2011. Term of approval is for 1 year from this date. Each Clinical Brief is approved for .25 Prescribed credits. Credit may be claimed for 1 year from the date of each Clinical Brief. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note: Total credit is subject to change based on topic selection and article length.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
AAFP Accreditation Questions
Medscape, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.
Accreditation of this program does not imply endorsement by either Medscape, LLC or ANCC.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.
*The credit that you receive is based on your user profile.
CME/CE Released: 9/15/2011
Valid for credit through: 9/15/2012, 11:59 PM EST
processing....
According to the current study by Castellsagué and colleagues, epidemiologic studies have consistently shown that the use of intrauterine devices (IUDs) reduces the risk for endometrial cancer, but the effect of IUD use on cervical cancer risk is not known. Because human papillomavirus (HPV) is now established as the cause of cervical cancer, HPV infection should be considered when the risk for cervical cancer with IUD use is examined.
This is a pooled analysis from 2 large studies consisting of 10 case-control studies done in 8 countries, and 16 studies of HPV prevalence from 16 countries. The goal of the analysis was to examine the risks for cervical cancer and HPV infection with IUD use.
Women with a history of using IUDs have a reduced risk — by almost half — of developing cervical cancer, compared with women who never used the birth control devices, according to a new pooled analysis from European researchers.
Epidemiologic studies have consistently shown that IUD use reduces the risk for endometrial cancer, but the device's effect on the risk for cervical cancer has not been determined, say the researchers, led by Xavier Castellsagué, MD, from theInstitut Català d'Oncologia in Catalonia, Spain.
Previous studies have reported "inconsistent results" in cervical cancer, and none accounted for either HPV status or Pap screening history, they write in a paper published online September 13 in the Lancet Oncology.
IUD use has been suspected of causing cervical cancer since its clinical introduction in the 1930s, add the authors.
The epidemiologic study of nearly 20,000 women found that women who used IUDs had a 45% reduced risk for cervical cancer, compared with never users.
Specifically, the researchers found a "strong" inverse association between ever-use of IUDs and cervical cancer (odds ratio [OR], 0.55; P < .0001) after adjustment for "relevant covariates." Those variables include the number of previous Pap tests that a woman has undergone.
A protective association was also noted for the 2 major cervical cancer histologic types — squamous cell carcinoma (OR, 0.56; P < .0001) and adenocarcinoma or adenosquamous carcinoma (OR 0.46; P = .035). However, there was no protective association among HPV-positive women (OR, 0.68; P =.11).
Thus, IUD use did not protect women against HPV infection, but did protect against the development of cervical cancer.
The researchers summarized what all these associations mean.
"The associations found in our study strongly suggest that IUD use does not modify the likelihood of prevalent HPV infection, but might affect the likelihood of HPV progression to cervical cancer," they write.
The results are "surprising" and should provide "restored confidence in the safety of IUDs," writes Karl Ulrich Petry, MD, from the Klinikum Wolfsburg in Germany, in an editorial that accompanies the study. The study "provides high-level evidence to contradict a widespread assumption that IUD use increases the risk of cervical cancer," he writes.
How IUDs Might Prevent Cervical Cancer
The mechanism of action by which IUDs protects against cervical cancer is not known, but the authors offer several explanations.
"One of the mechanisms by which IUDs might exert this protective effect is through the induction of a reactive, chronic, low-grade, sterile inflammatory response in the endometrium, endocervical canal, and cervix that could modify, via changes in the local mucosal immune status, the course of HPV infections," write the authors.
Another possible explanation accommodates an interesting finding in the study.
The investigators found that there was no difference in the protective effect by years of IUD use. Short-term users and those with use as long as 9 years were found to be protected, according to the odds ratio estimates.
"It can be postulated that the local trauma to the cervical tissue associated with insertion or removal of the device induces local small foci of chronic inflammation and a long-lasting immune response similar to that noted in patients after colposcopically guided punch biopsies," write the authors.
A theory that incorporates the concept of local trauma and subsequent immune response also appeals to Dr. Petry, the editorialist.
"I postulate that the tissue trauma associated with loop insertion induces a cellular immune response that might finally clear persistent HPV infections and preinvasive lesions," he writes.
The study's findings challenge some key elements of the "current model of the natural history of cervical cancer," adds Dr. Petry.
If prospective trials confirm the protective role of cervical trauma via the IUD loop insertion, then the medical world would "need to accept," he says, "that most studies of the natural course of cervical lesions in fact describe an artificial course, manipulated by biopsies cervical brushes, loop insertion, and other procedures."
The implications are profound, he suggests.
"It is very likely that we underestimated the true risk of progression of HPV infections and associated lesions, based on studies that relied on biopsy-proven diagnoses."
All of this means that "today's standard information for patients — that less than 1% of HPV infections progress to cancer" — does not reflect the true natural history that exists outside of clinical interventions, such as biopsies, Dr. Petry says. "The 6.5% lifetime risk for cervical cancer observed in remote areas without screening probably mirrors the true natural risk," he adds.
What About Screening Bias?
The study consisted of a pooled analysis of individual data from 2 large studies by the International Agency for Research on Cancer and Institut Català d'Oncologia research program on HPV and cervical cancer.
One study included data from 10 case–control studies of cervical cancer conducted in 8 countries; the other included data from 16 HPV prevalence surveys of women from the general population in 14 countries. There were 2205 women with cervical cancer and 2214 matched control women without cervical cancer from the case–control studies, and 15,272 healthy women from the HPV surveys.
"An important challenge" in interpreting the results can be found in the possible effect of a screening bias, say the authors. The insertion, follow-up, and removal of IUDs often involves "several visits to the gynecologist, providing many opportunities for these women to be directly diagnosed or screened for cervical cancer, through visual identification or repeated cervical cytology."
This is important because "the reduced risk of cervical cancer seen in IUD users might not be due to the biological effect of the device, but rather to the higher likelihood of more intensive cervical screening or diagnosis in these women compared with non-users," the authors point out.
But the investigators accounted for that possibility. "We estimated associations by specific strata of number of previous Pap smears women had until 12 months before diagnosis or study entry," they write. They did not find that more visits resulted in a significantly different likelihood of cervical cancer. "History of previous Pap smears did not significantly affect the observed inverse association between IUD use and risk of cervical cancer," they conclude.
Furthermore, the study population is an argument against the potential for screening bias, they say. "Since most of the populations included in these analyses are from developing areas of the world, where screening is opportunistic and has little effect in preventing cervical cancer, it is unlikely that screening bias would explain the observed inverse association."
Funding for this study came from the Instituto de Salud Carlos III; Agència de Gestió d'Ajuts Universitaris i Recerca; Marató TV3 Foundation; Bill & Melinda Gates Foundation; International Agency for Research on Cancer; European Community; Fondo de Investigaciones Sanitarias, Spain; Preventiefonds, the Netherlands; Programa Interministerial de Investigación y Desarrollo, Spain; Conselho Nacional de Desenvolvimiento Cientifico e Tecnologico, Brazil; and Department of Reproductive Health & Research, World Health Organization. The authors have disclosed no relevant financial relationships.
Lancet Oncol. Published online September 13, 2011. Abstract, Editorial
Related Link
The Association of Reproductive Health Professionals provides a downloadable patient education brochure, available in both
English and Spanish, entitled A Woman's Guide to Understanding IUDs.